Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Vilanterol 25mcg + Fluticasone Furoate 100mcg rota cap
Therapeutic Category
Pulmonary, Respiratory, Asthma
Dosage Form
Rota cap
Packaging Type
Bottle
Packaging
30 Capsules
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Flutialfa VF is a combination inhalation therapy designed to provide effective management of asthma and chronic obstructive pulmonary disease (COPD). Each Rota Cap contains Vilanterol (25 mcg), a long-acting beta-agonist (LABA), and Fluticasone Furoate (100 mcg), a potent inhaled corticosteroid (ICS). This dual-action formulation works synergistically to improve lung function, reduce inflammation, and alleviate respiratory symptoms.
Vilanterol acts by stimulating beta-2 adrenergic receptors in the airway smooth muscle, leading to bronchodilation and improved airflow. This helps to relieve symptoms such as wheezing and shortness of breath. Fluticasone Furoate, on the other hand, reduces airway inflammation and hyperreactivity, addressing the underlying causes of asthma and COPD. Together, these components provide comprehensive control of respiratory conditions, allowing patients to breathe more easily and engage in daily activities with greater comfort.
Common side effects may include throat irritation, hoarseness, headache, and increased risk of respiratory infections. Some patients may experience palpitations or muscle cramps. It is essential to monitor for any unusual symptoms during treatment.
Flutialfa VF is indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults.
Flutialfa VF should be used only as prescribed by a healthcare professional. Do not exceed the recommended dosage, and consult a doctor if symptoms do not improve or worsen
Store Flutialfa VF in a cool, dry place, away from direct sunlight and moisture. Ensure that it is kept out of reach of children.
Composition : Budesonide (0.5mg) Respule
Composition : Budesonide (100mcg) Inhaler
Composition : Budesonide (400mcg) + Formoterol (6mcg) Rota Caps
Composition : Budesonide (0.5mg) + Formoterol (20mcg) Respule
Composition : Formoterol (20mcg) + Budesonide (0.5mg) Respule
Composition : Levosalbutamol (1.25mg) + Budesonide (0.5mg) Respule
Composition : Glycopyrronium (25mcg) + Formoterol (12mcg)+ Budesonide (400 mcg) Rota Capsule
Composition : Formoterol 6mcg + Budesonide 400mcg Rota Capsule
Composition : Fluticasone Propionate 500mcg + Formoterol Fumarate 12mcg Life Cap
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Vilanterol combined with Fluticasone furoate has strong demand in the respiratory and pulmonology segment, making it a valuable product for pharma distributors, wholesalers, and franchise partners. It is widely prescribed for the long-term management of asthma and COPD, ensuring consistent prescription-driven demand in chronic care therapy.
Medical distributors and agencies benefit from the high and continuous demand for inhalation-based respiratory therapies. Vilanterol provides long-acting bronchodilation for improved airflow Fluticasone Furoate reduces airway inflammation and prevents exacerbations Commonly prescribed for asthma and chronic obstructive pulmonary disease (COPD) Used as maintenance therapy for long-term respiratory control Strong demand from pulmonologists, physicians, and respiratory clinics Rotacap format ensures easy inhalation and better patient compliance This makes it a strong, steady-moving product in the respiratory segment.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Vilanterol + Fluticasone Furoate Rotacaps with monopoly rights, promotional support, quality manufacturing standards, attractive packaging, and competitive pricing for distributors and wholesalers.
Wholesalers and franchise partners benefit from chronic prescription-based demand, repeat monthly sales in asthma/COPD patients, strong hospital and clinic usage, and stable long-term growth in the respiratory care segment.
Interested distributors, stockists, and pharma franchise partners can contact Cafoli LifeCare Pvt Ltd to discuss monopoly territory rights, pricing structure, marketing support, and complete respiratory product portfolio access to build a strong presence in the pulmonology and chronic care market.